New treatment for active vitiligo, checking blood markers
Treatments studied
Part of Skin clinical trials.
This trial tests a new treatment for people with active generalized vitiligo covering more than 5% of their body (not counting hands and feet). It also looks at a protein in the blood called s100B to see how it relates to the condition and treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active vitiligo that is spreading or getting worse, covering more than 5% of your body (excluding hands and feet).
- You have not taken any oral vitiligo medication in the last 3 months, or used any topical creams or ointments for vitiligo in the last 4 weeks.
- Your vitiligo is not just on your face, fingers, toes, or in a strip on one side, and does not affect only your mucous membranes.
- You are not taking any other medications that suppress your immune system.
- You do not have other skin conditions like psoriasis, lupus, or alopecia areata that could interfere with the study.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage safety study of a new drug called IBI3013. The trial tests how safe the drug is and how your body processes it. It enrolls healthy volunteers first, then people with vitiligo (loss of skin color) or severe alopecia areata (patchy hair loss).
This study uses a simple blood test to measure immune system signals (cytokines) that may indicate whether vitiligo is active or stable. The goal is to create a model that helps predict how the disease may progress.
This trial tests a new oral medication called ACT-777991 to see if it is safe and can help repigment skin in adults with non-segmental vitiligo (the most common type that affects both sides of the body). Participants must have at least a certain amount of pigment loss on the face and total body, and agree not to use other vitiligo treatments during the study.
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
This study tests a new drug called EI-001 for people with non-segmental vitiligo (a type where white patches appear on both sides of the body). It is for those whose vitiligo has not gotten better with standard treatments like creams or light therapy, or who cannot use those treatments.
This study tests a new medicine called FB102 for people with non-segmental vitiligo. It aims to see if the drug is safe and helps restore skin color.
Hear when a new Vitiligo, Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.